Current Report No. 24/2023 – Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.
Date prepared: 12/22/2023, 10:59 a.m.

In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, which is linked to the Company awaiting a significant growth in sales in the generic segment, the Management Board of Celon Pharma S.A. (the “Company”), hereby announces that it was informed about the decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products of December 21, 2023 concerning the issuance of marketing authorisation for one of the Company's products in this therapeutic category.

It constitutes a standard procedure element foreseen and required by pharmaceutical law. The decision of the aforementioned authority is not tantamount to launching of manufacture and sale of the product, however it does constitute an element necessary for its future marketing in Poland.